Gilead director sells 18,000 shares after option exercise

Q: At what prices were Anthony Welters’ GILD stock options exercised and shares sold?

Welters exercised options with exercise prices of $60.67 and $61.35 per share. He sold 18,000 shares of GILD common stock in multiple trades at prices ranging from $147.57 to $149.58 per share.

Q: How many GILD shares did Anthony Welters sell in this Form 4 filing?

He sold a total of 18,000 shares of Gilead Sciences common stock, executed through several open-market transactions on August 26, 2026, according to the Form 4 transaction summary.

Q: What types of securities were involved in Anthony Welters’ GILD Form 4?

The filing shows derivative securities in the form of non-qualified stock options that were exercised into 18,000 shares of common stock, followed by sales of those common shares in the open market.

GILEAD SCIENCES, INC.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

GILEAD SCIENCES, INC. (GILD) director Anthony Welters reported an exercise-and-sell transaction on August 26, 2026. He exercised non-qualified stock options covering 18,000 shares of common stock at exercise prices of $60.67 and $61.35 per share, acquiring 18,000 shares. He then sold 18,000 shares of GILD common stock in multiple open-market trades at prices ranging from $147.57 to $149.58 per share, pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 18,000 shares ($1.58M approx. pre-tax spread)

Exercise and Sale 8 txns

Insider WELTERS ANTHONY

Role Director

Sold 18,000 shs ($2.68M)

Approx. gross sale proceeds $2.68M

Approx. exercise cost $1.10M

Approx. pre-tax spread $1.58M

Type	Security	Shares	Price	Value
Exercise	Non-qualified Stock Option (Right to Buy) ^{F1, F6}	7,718	$0.00	$0.00
Exercise	Non-qualified Stock Option (Right to Buy) ^{F1, F7}	10,282	$0.00	$0.00
Exercise	Common Stock ^F1	7,718	$60.67	$468K
Sale	Common Stock ^{F1, F2}	3,118	$148.3106	$462K
Sale	Common Stock ^{F1, F3}	4,600	$148.824	$685K
Exercise	Common Stock ^F1	10,282	$61.35	$631K
Sale	Common Stock ^{F1, F4}	3,402	$148.2353	$504K
Sale	Common Stock ^{F1, F5}	6,880	$148.8227	$1.02M

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 5,569 contracts (Direct); Common Stock — 12,894 shares (Direct)

Footnotes (7)

F1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.
F2. Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3. Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F4. Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F5. Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F6. 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020.
F7. 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021.

Key Figures

Options Exercised: 18,000 shares of common stock Sell Transactions: 18,000 shares of common stock Exercise Price: $60.67 per share +4 more

7 metrics

Options Exercised 18,000 shares of common stock Exercised from non-qualified stock options on August 26, 2026

Sell Transactions 18,000 shares of common stock Total shares sold in open-market transactions on August 26, 2026

Exercise Price $60.67 per share Non-qualified stock option with expiration October 22, 2030

Exercise Price $61.35 per share Non-qualified stock option with expiration May 5, 2032

Sale Price Range $147.58 to $148.5799 per share Price range for one set of reported sales on August 26, 2026

Sale Price Range $148.58 to $149.5799 per share Price range for another set of reported sales on August 26, 2026

Rule 10b5-1 Plan Adoption Date May 27, 2026 Date the trading plan governing these transactions was adopted

Key Terms

Non-qualified Stock Option, Rule 10b5-1 trading plan, Exercise or conversion of derivative security, open market or private transaction

4 terms

Non-qualified Stock Option financial

"Non-qualified Stock Option (Right to Buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Rule 10b5-1 trading plan regulatory

"made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security"

open market or private transaction financial

"transaction_code_description": "Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GILD director Anthony Welters report?

Anthony Welters reported exercising non-qualified stock options for 18,000 shares of Gilead Sciences common stock and selling 18,000 shares in open-market transactions on August 26, 2026, as disclosed in a Form 4.

At what prices were Anthony Welters’ GILD stock options exercised and shares sold?

Welters exercised options with exercise prices of $60.67 and $61.35 per share. He sold 18,000 shares of GILD common stock in multiple trades at prices ranging from $147.57 to $149.58 per share.

How many GILD shares did Anthony Welters sell in this Form 4 filing?

He sold a total of 18,000 shares of Gilead Sciences common stock, executed through several open-market transactions on August 26, 2026, according to the Form 4 transaction summary.

Were Anthony Welters’ GILD trades under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026, indicating they were pre-arranged under that plan.

What types of securities were involved in Anthony Welters’ GILD Form 4?

The filing shows derivative securities in the form of non-qualified stock options that were exercised into 18,000 shares of common stock, followed by sales of those common shares in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/27/2026 - 06:45 PM EDT Accepted by SEC EDGAR 08/27/2026 - 06:44 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WELTERS ANTHONY

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/26/2026		M⁽¹⁾		7,718	A	$60.67	20,612	D
Common Stock	08/26/2026		S⁽¹⁾		3,118	D	$148.3106⁽²⁾	17,494	D
Common Stock	08/26/2026		S⁽¹⁾		4,600	D	$148.824⁽³⁾	12,894	D
Common Stock	08/26/2026		M⁽¹⁾		10,282	A	$61.35	23,176	D
Common Stock	08/26/2026		S⁽¹⁾		3,402	D	$148.2353⁽⁴⁾	19,774	D
Common Stock	08/26/2026		S⁽¹⁾		6,880	D	$148.8227⁽⁵⁾	12,894	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Option (Right to Buy)	$60.67	08/26/2026		M⁽¹⁾			7,718	⁽⁶⁾	10/22/2030	Common Stock	7,718	$0	0	D
Non-qualified Stock Option (Right to Buy)	$61.35	08/26/2026		M⁽¹⁾			10,282	⁽⁷⁾	05/05/2032	Common Stock	10,282	$0	5,569	D

Explanation of Responses:

1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

2. Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

4. Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

5. Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

6. 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020.

7. 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021.

Remarks:

	/s/ Amy Kim by Power of Attorney for Anthony Welters	08/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR